Invasive pulmonary aspergillosis in a COVID-19 recovered patient: unravelling an infective sequalae of the SARS-CoV-2 virus

Monaldi Arch Chest Dis. 2021 Apr 6;91(2). doi: 10.4081/monaldi.2021.1664.

Abstract

Dear Editor, A 55-year-female, house wife, non-smoker, morbidly obese (BMI>35) with no other co-morbidities or pre-existing lung disease presented to the emergency room with complaints of highgrade fever, cough with minimal sputum, progressive breathlessness, streaky haemoptysis, and anorexia for the past 5 days. She was admitted in intensive care unit (ICU) for severe COVID-19 pneumonia three months back and had successfully recovered after 24 days of hospitalization....

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antifungal Agents / therapeutic use
  • COVID-19 / complications*
  • COVID-19 / therapy
  • Coinfection
  • Critical Care
  • Female
  • Humans
  • Invasive Pulmonary Aspergillosis / complications*
  • Invasive Pulmonary Aspergillosis / diagnosis
  • Invasive Pulmonary Aspergillosis / drug therapy
  • Middle Aged
  • Obesity, Morbid / complications
  • SARS-CoV-2
  • Treatment Outcome
  • Voriconazole / therapeutic use

Substances

  • Antifungal Agents
  • Voriconazole